Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.

[1]  A. Sanyal,et al.  Burden of Disease due to Nonalcoholic Fatty Liver Disease. , 2020, Gastroenterology clinics of North America.

[2]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[3]  O. Cummings,et al.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.

[4]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[5]  Rohit Loomba,et al.  Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD , 2018, Hepatology.

[6]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[7]  Rohit Loomba,et al.  Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials , 2018, Hepatology.

[8]  C. Sirlin,et al.  Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis , 2018, Hepatology.

[9]  D. Kleiner.  Histopathology, grading and staging of nonalcoholic fatty liver disease. , 2018, Minerva gastroenterologica e dietologica.

[10]  J. Browning,et al.  Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[12]  M. Robson,et al.  Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[13]  William Carey,et al.  Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data , 2017, The American Journal of Gastroenterology.

[14]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[15]  K. Flegal,et al.  Trends in Obesity Among Adults in the United States, 2005 to 2014. , 2016, JAMA.

[16]  Matthew D. Robson,et al.  Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease , 2016, Journal of hepatology.

[17]  A. Diehl,et al.  Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications , 2015, Seminars in Liver Disease.

[18]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  Anthony Gamst,et al.  Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study , 2014, Hepatology.

[20]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[21]  Rohit Loomba,et al.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.

[22]  B. Neuschwander‐Tetri,et al.  Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients , 2013, Hepatology.

[23]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[24]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[25]  Ruixin Zhu,et al.  Systematic Analysis of the Gene Expression in the Livers of Nonalcoholic Steatohepatitis: Implications on Potential Biomarkers and Molecular Pathological Mechanism , 2012, PloS one.

[26]  D. Brenner,et al.  Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial , 2012, Hepatology.

[27]  L. Ferrell,et al.  Ethnicity and nonalcoholic fatty liver disease , 2012, Hepatology.

[28]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[29]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[30]  B. Neuschwander‐Tetri,et al.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.

[31]  Richard L Ehman,et al.  Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications , 2007, Hepatology.

[32]  R. Ross,et al.  Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. , 2006, Gastroenterology.

[33]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[34]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[35]  M. Saboorian,et al.  Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.

[36]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[37]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[38]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[39]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[40]  J. Patrie,et al.  Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.